Remove tag doctorly
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

If the drug is approved you can bet that it’s going to carry a huge price tag. It could carry a price tag as high as $50,000-a-year per patient, according to drug analysts, adding billions of dollars to the nation’s health tab. . Will they follow the science or will they put a price tag on hope?

Drugs 187
article thumbnail

What is Biogen and can they repair their reputation?

World of DTC Marketing

Then, against the advisory panel’s advice, Aduhelm was approved, but insiders within the industry criticized both the FDA and Biogen weren’t sold on the drug or its price tag. Many doctors also became upset at the idea of telling Alzheimer’s patients that the drug didn’t work.

Drugs 222
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. Analysts meanwhile have suggested that Aduhelm may start to pick up momentum if that review is positive.

Sales 115
article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

Tags #pctGR, @Collaboratory1 The post Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. We know there is a digital gap in disadvantaged patients and elderly patients. Many patients did not answer the phone.

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.

Radiology 111
article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

Not to mention the $56,000 annual price tag. SKIMMERS SUMMARY: Jefferies analysts found doctors have shown strong interest in prescribing Aduhelm for about 35% of early-stage Alzheimer’s patients with mild cognitive impairment after surveying 50 U.S. neurologists or psychiatrists currently treating about 12,000 Alzheimer’s patients.

Drugs 218
article thumbnail

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

pharmaphorum

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year.

Sales 111